Combined Screening with QF-PCR (Immulite)

Combined Screening with QF-PCR (Immulite)

Advanced Prenatal Screening for Chromosomal Abnormalities

Combined Screening with QF-PCR (Immulite) is a prenatal screening package designed to assess the risk of major chromosomal abnormalities in the fetus during early pregnancy. It combines maternal serum marker analysis using the Immulite platform with QF-PCR molecular testing for rapid chromosomal evaluation.

What the Test Includes

• First trimester maternal serum screening
• Biochemical marker analysis (PAPP-A & Free β-hCG)
• Risk assessment for:
  • Down Syndrome (Trisomy 21)
  • Edwards Syndrome (Trisomy 18)
  • Patau Syndrome (Trisomy 13)
• QF-PCR analysis for rapid detection of common chromosomal aneuploidies

Sample Required

• Maternal Serum
• Prenatal sample for QF-PCR (as advised by clinician)

Why This Test is Done

• Early assessment of fetal chromosomal risk
• Supports informed pregnancy management
• Provides faster confirmation through molecular testing
• Recommended for high-risk pregnancies or abnormal ultrasound findings

Methodology

• Immunoassay (Immulite)
• Quantitative Fluorescent PCR (QF-PCR)

Recommended During

• First trimester of pregnancy (typically 11–13 weeks)

Reporting Time

• As per laboratory protocol

Note

This is a screening and rapid diagnostic support test. Clinical correlation and genetic counseling are recommended for abnormal results.